Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Prognostic factors in soft tissue sarcoma

A Rydholm1

  • 1Department of Orthopedics, University Hospital, Sweden. anders.rydholm@ort.lu.se

Acta Orthopaedica Scandinavica. Supplementum
|February 1, 1997
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Simple guidelines for efficient referral of soft-tissue sarcomas: a population-based evaluation of adherence to guidelines and referral patterns.

The Journal of bone and joint surgery. American volume·2012
Same author

Nonrandom secondary chromosome-aberrations in liposarcomas with t(12, 16).

International journal of oncology·2011
Same author

Nonrandom secondary chromosome-aberrations in synovial sarcomas with t(x-18).

International journal of oncology·2011
Same author

Deep-seated ordinary and atypical lipomas: histopathology, cytogenetics, clinical features, and outcome in 215 tumours of the extremity and trunk wall.

The Journal of bone and joint surgery. British volume·2008
Same author

Chest wall sarcoma: outcome in 22 patients after resection requiring thoracic cage reconstruction.

Sarcoma·2008
Same author

Identification of low-risk tumours in histological high-grade soft tissue sarcomas.

European journal of cancer (Oxford, England : 1990)·2007
Same journal

Prognostic factors in soft tissue sarcoma. Tissue microarray for immunostaining, the importance of whole-tumor sections and time-dependence.

Acta orthopaedica Scandinavica. Supplementum·2005
Same journal

Lumbar spinal fusion. Outcome in relation to surgical methods, choice of implant and postoperative rehabilitation.

Acta orthopaedica Scandinavica. Supplementum·2004
Same journal

The Scandinavian Sarcoma Group 25 years' experience.

Acta orthopaedica Scandinavica. Supplementum·2004
Same journal

Scientific publications from the Scandinavian Sarcoma Centers 1998-2003.

Acta orthopaedica Scandinavica. Supplementum·2004
Same journal

Meniscal tear--a feature of osteoarthritis.

Acta orthopaedica Scandinavica. Supplementum·2004
Same journal

Chemotherapy in osteosarcoma. The Scandinavian Sarcoma Group experience.

Acta orthopaedica Scandinavica. Supplementum·2004
See all related articles

Reliable prognostic markers for soft tissue sarcoma are lacking, hindering accurate staging and chemotherapy trials. Future research may focus on metastasis detection rather than primary tumor characteristics.

Area of Science:

  • Oncology
  • Surgical Pathology
  • Cancer Prognostics

Background:

  • Current prognostic markers for soft tissue sarcoma (STS) lack consistent reproducibility in classification and prognostic strength across different studies and subtypes.
  • The absence of a universally accepted prognostic or staging system for STS complicates treatment decisions and clinical trial design.
  • Highly malignant STS may exhibit metastatic behavior at diagnosis, similar to bone tumors like osteosarcoma, necessitating improved detection methods.

Purpose of the Study:

  • To highlight the deficiencies in current prognostic marker systems for soft tissue sarcoma.
  • To emphasize the need for reliable prognosticators to identify high-risk patients for effective chemotherapy trials.
  • To explore alternative approaches for prognostication, potentially focusing on metastasis detection.

Related Experiment Videos

Main Methods:

  • Review and critical analysis of existing literature on prognostic markers in soft tissue sarcoma.
  • Comparison of STS prognostication with established systems for highly malignant bone tumors (osteosarcoma, Ewing sarcoma).
  • Discussion of the ideal characteristics of a prognostic system for optimizing patient stratification and clinical trials.

Main Results:

  • Existing prognostic markers for STS show poor reproducibility and variable prognostic strength.
  • No single histotype of STS is inherently associated with a uniformly poor prognosis, necessitating additional markers.
  • The ideal prognostic system would segregate patients into distinct high- and low-risk groups for targeted therapy and trials.

Conclusions:

  • There is a critical need for improved, reproducible prognostic markers and staging systems for soft tissue sarcoma.
  • Accurate prognostication is essential for designing effective chemotherapy trials by including only high-risk patients.
  • Future strategies may involve focusing on detecting metastasis rather than solely relying on primary tumor characteristics.